Clinical and Genetic Influencing Factors on Clozapine Pharmacokinetics

Plain-language summary

This study examined the clinical and genetic factors that influence how the drug clozapine is processed in the body (its pharmacokinetics) in patients with schizophrenia taking clozapine; blood clozapine levels were measured and genotyping was performed. It enrolled patients with schizophrenia who adhered well to clozapine treatment. It was a study without an assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Not Applicable

Status

Completed

Sponsor

University of Monastir

Intervention

Determination of plasma concentration of clozapine/ Genotyping

Start date

10/17/2019

Estimated completion

12/14/2019

Countries

Tunisia

Related genes

Locations

• Monastir, Tunisia

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Schizophrenic patients receiving clozapine
* Good adherence to the treatment (clozapine)

Exclusion Criteria:

* Patients who were co-prescribed drugs that affected the pharmacokinetics of Clozapine.
* Patients who presented gastrointestinal disorders disturbing absorption of clozapine.